Papillary Renal Cell Carcinoma

Watchlist

(log in to enable)

Retrieved

2022-04-26

Source

Gard

Trials

—

Genes

MET, MITF, PRCC, VHL, TFE3, KRT7, ERBB2, GSTP1, SLC2A1, ELOC, POMC, PIK3CA, ADIPOQ, RPL14, INPP4B, FPGT, TNFSF10, CRADD, UNC5C, TAGLN2, BAP1, KDM5C, PEBP1, MLLT10, PAK1, TSC1, TP53, TGM2, PDHB, HNF1B

MET, MITF, PRCC, VHL, TFE3, KRT7, ERBB2, GSTP1, SLC2A1, ELOC, POMC, PIK3CA, ADIPOQ, RPL14, INPP4B, FPGT, TNFSF10, CRADD, UNC5C, TAGLN2, BAP1, KDM5C, PEBP1, MLLT10, PAK1, TSC1, TP53, TGM2, PDHB, HNF1B, HNF1A, NF2, SOD2, SLC5A3, PGK1, ACY1, RYR1, RELA, PVALB, PTGS2, PTEN, ZNF536, ACHE, KEAP1, AHNAK, LMAN2L, CARD11, SLC49A4, NAV3, ZNF765, NLRP12, ZNF804A, CSMD3, LRRK2, ASB15, DNHD1, FAAH2, FLCN, OR4C13, VMO1, MSGN1, FAM111B, BIRC7, SPTBN4, CUL7, FMN2, NDRG1, CPQ, BTG3, AKAP13, RNF139, PDXDC1, SYNE2, PRAME, YIPF3, PNKD, SETD2, SHANK1, LRP1B, TET2, PBRM1, PIDD1, AP5M1, OGG1, SFRP2, APRT, MUC4, IL6, ALDH1A1, ALK, ALOX5, IFNA2, HSPD1, HSPB1, HSPA9, ALOX12B, ANXA4, APAF1, BIRC5, HARS1, EEF2, BCHE, GSTT1, GSTM1, GRB7, GJB1, EPAS1, MTOR, IL6R, IL4R, IL13, KRT32, CNN2, SCARB1, CASP2, CAPG, M6PR, ALAD, LDHB, L1CAM, CRABP1, KRT8, KCNMA1, DAPK1, CTSD, CTSB, CRYAB, FLT1, CDC73, HABP2, LMNA, FOXE1, MINPP1, VEGFA, AMACR, KDR, CD38, FH, MME, RASSF1, CA9, MYC, KIT, SNORD14D, SNORD14C, CD47, MIR1180, TWSG1, MIR1293, MIR379, KMT2C, ACE2, FBXO47, EIF2AK4, MIR34A, MIR200C, MIR181C, MIR134, MIR127, FBXO11, AKT1, DDR1, RAB37, APC, CDC34, SETDB2, BRAF, SNORD35B, RIOX2, BSG, BUB1, SNORD14E, SNORD14B, MEG3, DHCR24, LARP6, CDH1, HIF1A, TOP2A, TIMP3, TIMP1, UBE2K, SYP, IGFBP7, SLC16A1, SFPQ, RRM2, SNORD15A, CD82, PYCR1, PTK7, CFP, PAX2, MUC1, TBC1D25, OAT, NONO, NFE2L2, XRCC1, PAX8, FZD1, KDM4C, CDR2, CMA1, APH1A, CD274, CLDN7, MCTS1, MCAT, UBE2S, HAVCR1, ACE, CUL3, RALBP1, EGF, EGFR, ELAVL2, ETFA, NAPSA, FGFR2, FOLH1, GABPA, MIR3199-2

Drugs

(R, S)-3-(bromomethyl)-3-butanol-1-yl-diphosphate, 26 base single stranded phosphodiester DNA oligonucleotide, 4-amino-5-oxo-4 (pyridinium-1-ylmethyl) proline

(R, S)-3-(bromomethyl)-3-butanol-1-yl-diphosphate, 26 base single stranded phosphodiester DNA oligonucleotide, 4-amino-5-oxo-4 (pyridinium-1-ylmethyl) proline, Aldesleukin ( PROLEUKIN ), Autologous Tumor-Derived gp96 Heat Shock Protein-Peptide Complex ( ONCOPHAGE ), Autologous renal cell tumor vaccine, Axitinib ( INLYTA ), Bevacizumab ( Equidacent, AVASTIN, Aybintio, MVASI ), Everolimus ( AFINITOR, VOTUBIA ), Genetically modified allogeneic (human) tumour cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM), Girentuximab ( RENCAREX ), HLA class I/II binding tumour associated peptides (ADF-APO-CCN-GUC-K67-MET-MMPMMPMUC-RGS), Human interleukin-2 (glycosylated tetrasaccharide, glycosylated trisaccharide and nonglycosylated) (inhalation use), Humanized anti-KSA monoclonal antibody-human interleukin-2 fusion protein, Interferon gamma 1b ( ACTIMMUNE, IMUKIN ), Iodine (131I) chimeric IgG monoclonal antibody cG250, N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate, Naptumomab estafenatox, Pazopanib hydrochloride ( VOTRIENT ), Recombinant human interleukin-21, Recombinant modified vaccinia Ankara expressing human 5T4, Siltuximab ( SYLVANT ), Sorafenib tosylate ( NEXAVAR ), Sunitinib malate ( SUTENT ), Talactoferrinum alfa, Temsirolimus ( TORISEL )

Interested in hearing about new therapies?

Papillary renal cell carcinoma (PRCC) is a type of cancer that occurs in the kidneys. It accounts for about 10-15% of all renal cell carcinomas.R enal cell carcinoma s are a type of kidney cancer that develop in the lining of very small tubes (tubules) in the kidney.The term "papillary" describes the finger-like projections that can be found in most of the tumors. PRCC can be divided into two types: type 1, which is more common and usually grows more slowly and type 2, which are usually more aggressive .Though the exact cause of papillary renal cell carcinoma is unknown, smoking, obesity, and genetic predisposition conditions (such as hereditary leiomyomatosis and renal cell cancer) may contribute to the development of this type of cancer. Treatment often begins with surgery to remove as much of the cancer as possible, and may be followed by radiation therapy, chemotherapy, biological therapy, or targeted therapy.